Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
Related Articles
Sano M.
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
J Cardiol. 2018 May;71(5):471-476. doi: 10.1016/j.jjcc.2017.12.004. Epub 2018 Feb 4.
Packer M, Anker SD, Butler J, Filippatos G, Zannad F.
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
JAMA Cardiol. 2017 Sep 1;2(9):1025-1029. doi: 10.1001/jamacardio.2017.2275.
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW.
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Diabetes Obes Metab. 2018 Mar;20(3):479-487. doi: 10.1111/dom.13126. Epub 2017 Nov 15.
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com